Trial Profile
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Veliparib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 07 Mar 2023 Planned End Date changed from 15 Dec 2022 to 15 Dec 2024.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 16 Dec 2021 Planned End Date changed from 1 Dec 2021 to 15 Dec 2022.